JPH02109976A - Ｌａｋ活性リンパ細胞の調製法 - Google Patents

Ｌａｋ活性リンパ細胞の調製法

Info

Publication number
JPH02109976A
JPH02109976A JP63320314A JP32031488A JPH02109976A JP H02109976 A JPH02109976 A JP H02109976A JP 63320314 A JP63320314 A JP 63320314A JP 32031488 A JP32031488 A JP 32031488A JP H02109976 A JPH02109976 A JP H02109976A
Authority
JP
Japan
Prior art keywords
cells
lymphocytes
lak
plastic
cultured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63320314A
Other languages
English (en)
Japanese (ja)
Inventor
John C Hiserodt
ジョン　チャートフィールド　ヒセロット
Nikola L Vujanovic
ニコラ　エル　ヴヤノヴィク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of JPH02109976A publication Critical patent/JPH02109976A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP63320314A 1987-12-18 1988-12-19 Ｌａｋ活性リンパ細胞の調製法 Pending JPH02109976A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US134717 1987-12-18
US07/134,717 US5057423A (en) 1987-12-18 1987-12-18 Method for the preparation of pure LAK-active lymphocytes

Publications (1)

Publication Number Publication Date
JPH02109976A true JPH02109976A (ja) 1990-04-23

Family

ID=22464654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63320314A Pending JPH02109976A (ja) 1987-12-18 1988-12-19 Ｌａｋ活性リンパ細胞の調製法

Country Status (3)

Country Link
US (1) US5057423A (enExample)
JP (1) JPH02109976A (enExample)
FR (1) FR2624742A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892791A (en) * 1987-03-27 1990-01-09 Nihon Sinku Gijutsu Kabushiki Kaisha Body coated with cubic boron nitride & method for manufacturing the same

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2657783B1 (fr) * 1990-02-07 1992-05-29 Fondation Nale Transfusion San Procede de preparation de derives sanguins et derives obtenus par ce procede.
EP0726772B1 (en) * 1993-08-09 2001-11-07 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7361332B2 (en) * 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
ATE338813T1 (de) * 1995-03-17 2006-09-15 Univ California Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
US5627070A (en) * 1995-07-26 1997-05-06 Celltherapy, Inc. Cell growing device for in vitro cell population expansion
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
WO1997032970A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes
JP2002516562A (ja) 1996-03-04 2002-06-04 ターゲティッド ジェネティックス コーポレイション Ｔリンパ球のインビトロ増殖のための改変された迅速な拡大方法（「改変ｒｅｍ」）
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
CN1541113A (zh) * 2001-04-27 2004-10-27 �Ƹ��� 利用激活的t细胞使抗原提呈细胞成熟
US20050226857A1 (en) * 2001-06-01 2005-10-13 Xcyte Therapies, Inc. T cell therapy for the treatment of cachexia and chronic diseases
KR20040048379A (ko) * 2001-06-01 2004-06-09 싸이트 테라피스 인코포레이티드 Ｔ 세포 유도된 조직 복구 및 재생
ATE429486T1 (de) 2001-08-15 2009-05-15 Takara Bio Inc Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
EP2034009B1 (en) 2002-02-08 2014-01-15 Life Technologies Corporation Compositions and methods for restoring immune responsiveness in patients with immunological defects basing on cd3/cd28 costimulation
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US20040151704A1 (en) 2002-06-28 2004-08-05 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
DE10319430B4 (de) * 2003-04-29 2009-01-15 Max Hauser Süddeutsche Chirurgiemechanik GmbH Vorrichtung zum Spreizen von Gewebe
DE60334250D1 (de) * 2003-05-08 2010-10-28 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t-zellen
CA2539716A1 (en) * 2003-09-22 2005-04-07 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery
DE602004030369D1 (de) * 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
PL2435825T3 (pl) 2009-05-27 2015-12-31 Biotempus Ltd Sposoby leczenia chorób
JP6392315B2 (ja) 2013-03-14 2018-09-19 イミュソフト コーポレーション インビトロでのメモリーｂ細胞分化方法およびｖｓｖ−ｇ偽型ウイルスベクターを用いる形質導入方法
EP4177336A1 (en) 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
WO2017182608A1 (en) 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions for the treatment of b-cell malignancies
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US20250152714A1 (en) 2023-11-15 2025-05-15 Immusoft Corporation Migratory modified differentiated b cells for cancer therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4849329A (en) * 1986-05-30 1989-07-18 E. I. Du Pont De Nemours And Company Process for preparing lymphokine activated killer cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892791A (en) * 1987-03-27 1990-01-09 Nihon Sinku Gijutsu Kabushiki Kaisha Body coated with cubic boron nitride & method for manufacturing the same

Also Published As

Publication number Publication date
US5057423A (en) 1991-10-15
FR2624742A1 (fr) 1989-06-23
FR2624742B1 (enExample) 1993-02-26

Similar Documents

Publication Publication Date Title
US5057423A (en) Method for the preparation of pure LAK-active lymphocytes
JP7451468B2 (ja) 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用
Clark et al. A novel method for the isolation of skin resident T cells from normal and diseased human skin
Cooper et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
AU738538B2 (en) Method for the production of selected lymphocytes
Zeng et al. Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance
Vujanovic et al. Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.
Okazaki et al. IL-7 promotes thymocyte proliferation and maintains immunocompetent thymocytes bearing alpha beta or gamma delta T-cell receptors in vitro: synergism with IL-2.
CN1180079C (zh) 在三维装置中从造血祖细胞产生淋巴组织-特异细胞
JP4714767B2 (ja) ヒト血液由来のｃｄ４＋ｃｄ２５＋調節ｔ細胞
US12460180B2 (en) Methods for isolating and expanding cells
KR20250080907A (ko) γδ T 세포의 증식, 조성물 및 이의 사용 방법
WO1991005037A1 (en) Extracellular matrix protein adherent t cells
CN111918963A (zh) 表达趋化因子受体和细胞粘附分子的cd3阴性细胞群体及其用途和制备方法
CN113462646A (zh) 一种简单有效的诱导扩增iNKT细胞的方法及应用
CN115558641B (zh) 高纯度效应免疫细胞群及其培养方法、试剂组合物和应用
US20220010277A1 (en) Methods for isolating and expanding cells
CN113046313A (zh) 用于高效诱导扩增人体外周血杀伤性免疫细胞的组合物、试剂盒以及该免疫细胞的培养方法
JP4309047B2 (ja) 病的免疫応答を抑制するサイトカインおよびマイトジェンの使用
Moss et al. Proliferation of a subpopulation of human peripheral blood monocytes in the presence of colony stimulating factors may contribute to the inflammatory process in diseases such as rheumatoid arthritis
Managlia et al. Interleukin‐7 signalling is sufficient to phenotypically and functionally prime human CD4+ naïve T cells
WO2021123927A1 (en) Method of generation of lympho-myeloid niches
EP4534653A1 (en) Method for in-vitro induction amplification of nk cells with high purity and high cytotoxic activity
EP3752598B1 (en) Allogeneic composition
GAO et al. Generation of dendritic cell‐like antigen‐presenting cells in long‐term mixed leucocyte culture: phenotypic and functional studies